The value of urinary BDNF levels on assessment of the botulinum toxin type A treatment for neurogenic detrusor overactivity in children with myelodysplasia

How do we make progress in phenotyping patients with lower urinary tract such as overactive bladder and underactive detrusor, including using urine markers and microbiome data, to personalize therapy? ICI‐RS 2023—Part 2

“…Urine microbiome have recently been studied in different patient populations such as male LUTS/BPO, 42,43 interstitial cystitis/bladder pain syndrome and recurrent UTI 44 . However, there has been no consensus between the findings of these studies for any microbiome for any LUTD.Pediatric neurogenic population has been another target of urine biomarker research aiming to predict upper urinary tract damage response to botulinum neurotoxin injection 45,46 and bladder compliance 47 studying urinary NGF, TGF‐β1, TIMP‐2, and BDNF. A very recent systematic review on pediatric population has just been published pointing that prospective studies with larger sample sizes are needed to better understand the potential of urinary biomarkers to reflect urodynamic and clinical findings in children with LUTD 48 .…”

“…Pediatric neurogenic population has been another target of urine biomarker research aiming to predict upper urinary tract damage response to botulinum neurotoxin injection 45,46 and bladder compliance 47 studying urinary NGF, TGF‐β1, TIMP‐2, and BDNF. A very recent systematic review on pediatric population has just been published pointing that prospective studies with larger sample sizes are needed to better understand the potential of urinary biomarkers to reflect urodynamic and clinical findings in children with LUTD 48 .…”